vs
Side-by-side financial comparison of Oruka Therapeutics, Inc. (ORKA) and Roivant Sciences Ltd. (ROIV). Click either name above to swap in a different company.
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for unmet medical needs, primarily in oncology and immunology disease areas. It operates mainly in the United States, advancing its proprietary pipeline of drug candidates to address hard-to-treat patient populations across core therapeutic segments.
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
ORKA vs ROIV — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $0 | $2.0M |
| Net Profit | $-22.2M | $-265.9M |
| Gross Margin | — | — |
| Operating Margin | — | -16966.1% |
| Net Margin | — | -13301.2% |
| Revenue YoY | — | -77.8% |
| Net Profit YoY | -1402.9% | -257.0% |
| EPS (diluted) | $-6.96 | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $1.6M | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | — | $-39.6M | ||
| Q4 24 | — | $9.0M | ||
| Q3 24 | — | $4.5M | ||
| Q2 24 | $0 | $8.0M | ||
| Q1 24 | $0 | $28.9M |
| Q4 25 | — | $-265.9M | ||
| Q3 25 | — | $-113.5M | ||
| Q2 25 | — | $-223.4M | ||
| Q1 25 | — | $-206.5M | ||
| Q4 24 | — | $169.4M | ||
| Q3 24 | — | $-230.2M | ||
| Q2 24 | $-22.2M | $95.3M | ||
| Q1 24 | $-2.0M | $-151.1M |
| Q4 25 | — | -16966.1% | ||
| Q3 25 | — | -19492.9% | ||
| Q2 25 | — | -13130.0% | ||
| Q1 25 | — | 674.8% | ||
| Q4 24 | — | -3042.6% | ||
| Q3 24 | — | -7636.0% | ||
| Q2 24 | — | -1279.5% | ||
| Q1 24 | — | -919.5% |
| Q4 25 | — | -13301.2% | ||
| Q3 25 | — | -7225.9% | ||
| Q2 25 | — | -10292.9% | ||
| Q1 25 | — | 521.8% | ||
| Q4 24 | — | 1878.3% | ||
| Q3 24 | — | -5143.8% | ||
| Q2 24 | — | 1192.7% | ||
| Q1 24 | — | -522.3% |
| Q4 25 | — | $-0.38 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.33 | ||
| Q1 25 | — | $-0.28 | ||
| Q4 24 | — | $0.23 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | $-6.96 | $0.12 | ||
| Q1 24 | $-0.14 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.3M | $4.5B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-29.0M | $4.3B |
| Total Assets | $33.8M | $5.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.5B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.9B | ||
| Q4 24 | — | $5.1B | ||
| Q3 24 | — | $5.4B | ||
| Q2 24 | $33.3M | $5.7B | ||
| Q1 24 | $35.9M | $6.5B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $311.7M | ||
| Q1 24 | — | $430.6M |
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | — | $4.3B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $5.2B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | $-29.0M | $5.4B | ||
| Q1 24 | $-7.1M | $6.0B |
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | $6.2B | ||
| Q2 24 | $33.8M | $6.5B | ||
| Q1 24 | $36.7M | $7.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $-196.5M |
| Free Cash FlowOCF − Capex | — | $-201.4M |
| FCF MarginFCF / Revenue | — | -10076.0% |
| Capex IntensityCapex / Revenue | — | 246.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-776.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-196.5M | ||
| Q3 25 | — | $-185.7M | ||
| Q2 25 | — | $-204.4M | ||
| Q1 25 | — | $-172.6M | ||
| Q4 24 | — | $-207.3M | ||
| Q3 24 | — | $-266.8M | ||
| Q2 24 | $-2.6M | $-192.8M | ||
| Q1 24 | $-1.5M | $-108.5M |
| Q4 25 | — | $-201.4M | ||
| Q3 25 | — | $-193.5M | ||
| Q2 25 | — | $-208.4M | ||
| Q1 25 | — | $-173.4M | ||
| Q4 24 | — | $-209.1M | ||
| Q3 24 | — | $-267.8M | ||
| Q2 24 | — | $-193.8M | ||
| Q1 24 | — | $-108.8M |
| Q4 25 | — | -10076.0% | ||
| Q3 25 | — | -12317.8% | ||
| Q2 25 | — | -9604.5% | ||
| Q1 25 | — | 438.1% | ||
| Q4 24 | — | -2318.5% | ||
| Q3 24 | — | -5984.4% | ||
| Q2 24 | — | -2425.5% | ||
| Q1 24 | — | -376.1% |
| Q4 25 | — | 246.9% | ||
| Q3 25 | — | 499.6% | ||
| Q2 25 | — | 185.9% | ||
| Q1 25 | — | -2.0% | ||
| Q4 24 | — | 20.3% | ||
| Q3 24 | — | 22.3% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | — | 1.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -1.22× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.02× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
